China Pharma Holdings financials
$0.7150−4.87%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $948.3K | $983.5K | $1.2M | $756.2K | $1.0M | $1.1M | $1.1M | $1.1M | $924.9K | $1.4M | $2.1M | $1.8M |
| Gross profit | $83.6K | $285.5K | $150.8K | -$59.7K | -$87.0K | -$136.1K | -$160.6K | -$519.6K | -$1.0M | -$290.0K | -$79.2K | -$233.2K |
| Gross margin | 8.8% | 29.0% | 12.3% | −7.9% | −8.5% | −12.0% | −14.2% | −47.2% | −109.8% | −21.2% | −3.7% | −12.9% |
| Operating income | -$1.4M | -$1.1M | -$1.2M | -$628.1K | -$501.4K | -$758.6K | -$1.2M | -$1.1M | -$1.4M | -$916.1K | -$1.2M | -$713.5K |
| Net income | -$1.5M | -$1.1M | -$1.2M | -$651.5K | -$528.4K | -$785.6K | -$1.2M | -$1.1M | -$1.4M | -$955.9K | -$1.2M | -$777.6K |
| Net margin | −153.8% | −116.2% | −99.7% | −86.2% | −51.5% | −69.1% | −108.0% | −101.6% | −155.5% | −69.8% | −57.3% | −43.1% |
| Diluted EPS | $-0.04 | $-0.04 | $-0.18 | $-0.17 | $-0.16 | $-0.24 | $-0.53 | $-0.65 | $-0.89 | $-0.72 | $-1.62 | $-2.90 |
| EBITDA | -$330.0K | -$136.7K | -$702.8K | -$272.1K | -$180.6K | -$429.3K | -$748.0K | -$388.3K | -$652.3K | -$182.3K | -$488.7K | -$30.4K |
| Operating cash flow | -$32.8K | -$55.3K | $152.0K | -$237.0K | $274.3K | -$73.7K | $298.8K | -$47.0K | -$72.7K | -$585.2K | -$22.3K | $1.0M |
| Free cash flow | -$32.8K | -$55.3K | $151.5K | -$237.6K | $274.2K | -$132.0K | $279.2K | -$56.2K | -$100.8K | -$585.2K | -$33.8K | $1.0M |
| Diluted shares | 40.5M | 25.6M | 6.8M | 3.9M | 3.2M | 3.3M | 2.3M | 1.7M | 1.6M | 1.3M | 0.8M | 0.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $304.9K | $168.5K | $345.1K | $267.6K | $625.0K | $412.7K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $26.7K | $0.00 | $0.00 |
| Total debt | $3.6M | $3.4M | $3.4M | $3.4M | $3.4M | $3.5M |
| Total assets | $44.7M | $45.1M | $31.0M | $15.8M | $13.8M | $14.2M |
| Total liabilities | $8.5M | $8.1M | $8.3M | $7.5M | $7.3M | $7.2M |
| Shareholders' equity | $36.2M | $37.0M | $22.7M | $8.3M | $6.5M | $7.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology